Article

Clinical proof of concept for anti-FGF2 therapy in exudative age-related macular degeneration: phase 1 and phase 2 trials in treatment-naïve and anti-VEGF pretreated patients

2023-03-08

Abstract excerpt

<title>Abstract</title> <p>Intravitreal injections of anti-vascular endothelial growth factor (VEGF) agents are the first-line treatment for exudative/wet age-related macular degeneration (wet AMD). Alternative mechanisms of action may be helpful for treatment of this very common disease. Here we investigated an anti-fibroblast growth factor-2 (FGF2) aptamer, RBM-007, a next generation therapeutic for the treatme...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: e80a1170-b0d1-5985-a715-e4d838cafd95
DOI: 10.21203/rs.3.rs-2656731/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Clinical proof of concept for anti-FGF2 therapy in exudative age-related macular degeneration: phase 1 and phase 2 trials in treatment-naïve and anti-VEGF pretreated patientsDOI 10.21203/rs.3.rs-2656731/v1Read

A New Generation of Gene Therapies as the Future of Wet AMD TreatmentSemantic proximity Read

New Generation of Gene Therapies as the Future of Wet AMD TreatmentSemantic proximity Read

Preclinical development of a dual targeting bicistronic gene therapy approach for the treatment of wet age-related macular degenerationSemantic proximity Read

A Systematic Review; Efficacy Assessment of Novel Therapy in Treating Age-related Macular DegenerationSemantic proximity Read

Gene therapy for age-related macular degeneration: a promising frontier in vision preservationSemantic proximity Read

Advancements in age-related macular degeneration treatment: From traditional anti-VEGF to emerging therapies in gene, stem cell, and nanotechnologySemantic proximity Read

Gene Therapy for Non-Hereditary Retinal Disease: Age-Related Macular Degeneration, Diabetic Retinopathy, and BeyondSemantic proximity Read

Gene therapy for age-related macular degenerationSemantic proximity Read

Discovery of Aptamers and the Acceleration of the Development of Targeting Research in OphthalmologySemantic proximity Read

The 20th Anniversary of Pegaptanib (MacugenTM), the First Approved Aptamer Medicine: History, Recent Advances and Future Prospects of Aptamers in TherapySemantic proximity Read

Genetic biomarkers in the VEGF pathway predicting response to anti-VEGF therapy in age-related macular degenerationSemantic proximity Read